0.67
+0.01(+1.52%)
Currency In USD
Address
1325 Avenue of Americas
New York City, NY 10019
United States of America
Phone
201 488 0460
Sector
Healthcare
Industry
Biotechnology
Employees
27
First IPO Date
October 07, 2003
| Name | Title | Pay | Year Born |
| Mr. Chaim Lebovits | President & Chief Executive Officer | 649,588 | 1971 |
| Mr. Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary & Director | 230,027 | 1977 |
| Dr. Ibrahim Dagher M.D. | Executive Vice President & Chief Medical Officer | 426,723 | 1969 |
| Ms. Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs | 0 | N/A |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor | 0 | N/A |
| Dr. Hartoun Hartounian Ph.D. | Executive Vice President & Chief Operating Officer | 0 | 1960 |
| Dr. Netta Blondheim-Shraga Ph.D. | Senior Vice President of Research and Development | 0 | N/A |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
